

Collaborative Working Agreement Summary

1. Project Name:	Understanding Obesity Pathways in Greater Manchester ICS
2. Organisations involved with this Joint Working Project are:	Eli Lilly & Company (Lilly UK) Health Innovation Manchester (HInM)
3. The objectives for this project are:	<p>This project aims to develop a baseline pathway map of the 4 tier obesity services across Greater Manchester complete with capacity and demand data, patient eligibility criteria, treatment target attainment and patient attrition at each tier.</p> <p>The project will identify successes and failures with the current model including gaps in service provision and capacity by tier. By mapping patient journeys across services, the project will provide a complete picture of weight management services across Greater Manchester validated by local data.</p> <p>There are a number of licensed medications, as well as lifestyle and medical/surgical interventions to manage obesity. Obesity treatment provides an opportunity to improve patient outcomes. However, in order to maximise the impact of any interventions, there needs to be an effective and efficient obesity service. This project will provide the basis for a potential future collaborative working project redesigning the obesity pathway to improve patient outcomes.</p> <p>This project will be run as a CWA in line with Clause 20 of the 2021 ABPI Code of Practice. Any benefits realised from the CWA i.e. improved clinic efficiencies will be realised at an organisational level by Health Innovation Manchester.</p> <p>No individual healthcare professional will benefit from the implementation of this Agreement.</p>
4. Roles and Responsibilities, including any funding	<p>Lilly UK:</p> <ul style="list-style-type: none"> • Support initial project scoping, design and planning including co-development of project plans and other core project documents. • Certification of Project Initiation Document (PID) and executive summary and development of Agreement in line with ABPI code of practice requirements. • General project administrative support • Pathway mapping support and co-facilitation of Pathway Insight Group Workshop(s) • Capacity and Demand Pathway Mapping to support baseline and evaluation by Tranoca – a Lilly approved Vendor • Support publication of results in appropriate clinical and trade press (draft documentation will be shared any NHS organisations named in publications for approval) • Support for training and educational materials for relevant HCPs

Collaborative Working Agreement Summary

	<ul style="list-style-type: none"> • Stakeholder engagement support and wider implementation planning with strategic bodies such as ICS and Office for Life Sciences <p>At no point during this project will Lilly have access to any patient identifiable data.</p> <p>Health Innovation Manchester:</p> <ul style="list-style-type: none"> • Co-development of all project documentation • Responsible for HInM governance process with regards to entering into this agreement • Understanding of HInM process for receiving services and funding associated with this Agreement • Stakeholder management between HInM, Greater Manchester ICS, GMMMG • Baseline data provision through existing databases and / or development of ‘gap’ data collection plan including provision of a ‘test site’ to obtain GP data / Trust data • Organisation, management and co-facilitation of Pathway Insight Group Meeting(s) • Dissemination of results including write up for publication in clinical press <p>Financial details</p> <p>Lilly resource costs estimated £20,000</p> <p>Health Innovation Manchester resource costs estimated £20,000</p>
5. The expected benefits for patients on delivery of this project are:	Collaborative working – No planned improvement in patient care but standard of care will be maintained.
6. The expected benefits for the partner organisation(s) on delivery of this project are:	A greater understanding of weight management services across Greater Manchester for future service improvement.
7. The expected benefits for Lilly UK on delivery of this are:	An understanding of weight management services across Greater Manchester which can be translated to learnings across the UK. Insights on the appropriate use of obesity licensed medicines in line with NICE guidelines; identifying potential future needs for the weight management services and patients, which may inform future service offerings.